IgM antibody against hepatitis B core antigen (IgM anti-HBc), a marker of recent hepatitis B virus infection, was sought by radioimmunoassay in sera diluted 1/4000 from 376 patients presenting to four centres in Italy with acute, apparently type B hepatitis (hepatitis B surface antigen (HBsAg) positive).
Introduction
Testing with sensitive immunoassays for IgM antibody against hepatitis B core antigen (IgM anti-HBc) shows that reactivity is invariably present in acute hepatitis B but usually absent or detectable only at low titres in asymptomatic carriers of hepatitis B surface antigen (HBsAg) . ' -8 Longitudinal studies confirm that IgM anti-HBc is increased early during primary hepatitis B virus infection and then declines in a few months regardless of the persistence of circulating HBsAg.4 In view of the temporal relation to recent hepatitis B virus infection measurement of the IgM antibody might help to distinguish true hepatitis B from non-B hepatitis occurring in previously unrecognised carriers of HBsAg; many of these patients presenting with an acute liver illness are likely to be diagnosed as hepatitis B on finding HBsAg in the serum.
To determine the clinical value of IgM anti-HBc, this serum marker was measured by radioimmunoassay in 376 patients with Includes four with abnormal alanine aminotransferase activity.
t Includes 31 with abnormal alanine aminotransferase activity.
Discussion
In this study optimal discrimination between recent and old hepatitis B virus infection was achieved with a radioimmunoassay for IgM anti-HBc performed in sera diluted 1/4000, at which controls with acute hepatitis B yielded invariably positive reactions, wheras chronic asymptomatic carriers of HBsAg gave consistently negative results.
In most of the patients presenting with acute HBsAg hepatitis the finding of IgM anti-HBc confirmed that the illness was due to primary infection with hepatitis B virus. In each of the series examined, however, some of the patients lacked the IgM marker and were therefore considered to be previously unrecognised carriers of HBsAg presumably suffering from non-B hepatitis. In keeping with this, on admission to hospital many of them had circulating anti-HBe, which represents a marker of inactive infection14; HBeAg was usually found in the serum of patients positive for IgM anti-HBc as typical of classical acute hepatitis B.14 Further serological analysis often disclosed delta infection and occasionally hepatitis A or cytomegalovirus infection as the true cause of the illness. An additional factor could not be identified in some of the patients; undefined non-A non-B viruses of hepatitis or reactivation of the latent hepatitis B virus infection may have been implicated as the possible cause of the hepatitic episode.
As expected, during follow up HBsAg persisted in the serum of many patients without the IgM antibody, whereas among patients with the IgM marker the antigen cleared in almost all.
Clinically, therefore, a negative IgM anti-HBc test result predicts the carriage of HBsAg.
Our data show that testing for IgM anti-HBc is important in patients developing an apparent hepatitis B of unrelenting course: a similar clinical entity is mimicked by progressive non-B hepatitis in previously unrecognised carriers of HBsAg, and in this study accounted for most of the cases of HBsAg hepatitis destined to become chronic. A negative IgM anti-HBc test result should prompt search for a cause of the liver damage other than hepatitis B virus.
The magnitude of the problem of false hepatitis B is likely to be proportional to the prevalence of carriage of HBsAg in the population. In our study, however, the relation was not numerical, as in each series examined the proportion of patients negative for IgM anti-HBc was higher than the local rate of carriage.
Though a minority of the IgM anti-HBc negative patients were drug addicts or patients receiving dialysis and therefore heavily exposed to blood borne hepatitis viruses, an epidemiological factor was not obvious in the others. The implication might be that the HBsAg carrier state determines an increased biological susceptibility to hepatitis by multiple viral and possibly non-viral factors. This was shown for delta, a defective virus that is rescued and activated only by HBs antigenaemia.15
SHORT REPORTS Arthropathy induced by beta blockade
Few reports on arthropathy induced by beta blockade have been published. Pain and swelling of both knees developed in a man who took practolol for nearly three years after a myocardial infarction, subsided when he stopped the drug, and recurred when he took it again.' Polyarthritis has been described in association with propranolol and oxprenolol2; the same author described a similar case attributable to propranolol.
Paradoxically, propranolol exerts a favourable effect on arthritis.3 The mechanism of action remains to be established. The effect probably occurs as a result of the membrane stabilising or anaesthetic properties of the drug; beta receptor blockade does not seem to be a factor.4
In 1980 I began to look for possible cases of arthropathy induced by beta blockade after a patient's shoulder complaint subsided soon after metoprolol was stopped.
Patients, methods, and results
Patients were considered to have suffered from arthropathy induced by beta blockade if their joint symptoms developed during administration of a beta blocker and subsided only after the drug was stopped (or after a change to a different beta blocker). All the patients were seen at this hospital or my private surgery and came from a region of about 25 000 inhabitants.
Eighteen patients (mean age 64 years, range 45-74 years) were seen with arthropathy induced by beta blockade; six had been taking beta blockers for more than five years and seven for more than two years. The primary indication was hypertension or coronary heart disease or both. In every case an attempt was made to exclude other causes of joint symptoms by radiology and serological tests for rheumatoid disease. Fifteen patients had symptoms affecting the shoulder joint. These consisted mainly of discomfort on moving the arms and limitation of movement due to pain when the patient tried to raise the arm above the horizontal. Some patients complained of pain and stiffness at rest. None had joint effusion. Radiological examination generally disclosed slight thickening of the soft tissues surrounding the shoulder joint. Nine of the 15 had symptoms in other joints as well. Apart from the shoulder, the knee was most commonly affected (six patients). Five patients had symptoms of polyarthritis. Two patients complained of swelling and stiffness of the small finger joints.
The primary beta blocker used was metoprolol (table) . Those patients who developed joint symptoms with propranolol were given metoprolol as the first alternative. All reported exacerbation of the joint symptoms. Associated symptoms such as dry mouth and eye complaints were common as well (table) . Despite attempts to substitute other beta blockers for metoprolol and propranolol the same pattern of adverse effects tended to recur, so that beta blockade eventually had to be stopped in 12 of the 18 patients. All the joint symptoms (and the associated complaints) resolved promptly in the patients.
Comment
Joint disturbance must be considered to be a common adverse effect associated with beta blockade. Other adverse effects, notably eye symptoms, dry mouth, and Raynaud's phenomenon, were also common, which points to some common factor, most probably dehydration of mucous membranes and synovia induced by the drug.
